Answers are grounded in this paper and cite their sources.
Narrative review reveals advances in molecular mechanisms and clinical trials in amyotrophic lateral sclerosis, highlighting emerging gene therapies and multidisciplinary care.
In the last few years, our understanding of disease molecular mechanisms underpinning ALS has advanced greatly, allowing the first steps in translating into clinical practice novel research findings, including gene therapy approaches. Similarly, the recent advent of assistive technologies has greatly improved the possibility of a more personalized approach to supportive and symptomatic care, in the context of an increasingly complex multidisciplinary line of actions, which remains the cornerstone of ALS management. Against this rapidly growing background, here we provide an comprehensive update on the most recent studies that have contributed towards our understanding of ALS pathogenesis, the latest results from clinical trials as well as the future directions for improving the clinical management of ALS patients.
No takes yet. Share an insight, caveat, or question.
Riva et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: